Oncopeptides AB (OM:ONCO) Price Target Decreased by 25.00% to 5.29

Oncopeptides AB (OM:ONCO) has experienced a significant downward revision in its average one-year price target, which now stands at 5.29 kr per share, a 25.00% decrease from the prior estimate of 7.05 kr. This updated target is marginally below the latest closing price by 0.78%. Concurrently, institutional sentiment appears to be deteriorating, as total shares owned by institutions declined by 41.02% over the last three months, with SPEU - SPDR(R) Portfolio Europe ETF notably reducing its holdings by nearly 70%.

Analysis

Oncopeptides AB (OM:ONCO) has experienced a significant downward revision in its average one-year price target, which now stands at 5.29 kr per share. This represents a substantial 25.00% reduction from the prior estimate of 7.05 kr, indicating a material shift in analyst outlook. The updated target is marginally below the latest reported closing price of 5.33 kr, suggesting limited near-term upside potential based on current consensus.

This negative analyst sentiment is strongly corroborated by a notable decline in institutional holdings. Total shares owned by institutions decreased by 41.02% over the last three months, falling to 8K shares. While one fund maintains its position, the overall institutional activity points to a clear divestment trend.

Specifically, SPEU - SPDR(R) Portfolio Europe ETF, a significant holder, reduced its position in ONCO by 69.56%, divesting 6K shares. This firm also decreased its portfolio allocation in ONCO by 4.16% over the last quarter. The combination of a sharply reduced price target and significant institutional selling signals a strongly bearish outlook for the company.

Key Decisions for Investors

• Investors currently holding ONCO should re-evaluate their position given the substantial 25.00% price target downgrade and significant institutional selling pressure.
• Prudent investors should closely monitor any new company announcements or further changes in analyst ratings and institutional ownership, as these could indicate a continued negative trend or potential stabilization.
• The current average price target being marginally below the latest closing price, coupled with strong negative sentiment and institutional divestment, suggests potential downside risk and limited near-term upside.